Health Care & Life Sciences » Pharmaceuticals | Amicus Therapeutics Inc.

Amicus Therapeutics Inc.

Amicus Therapeutics Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
189.13 M
Public Float
187.04 M
Amicus Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$2.14
Market Cap
$3.02 B
Shares Outstanding
254.33 M
Public Float
217.92 M

Profile

Address
1 Cedar Brook Drive
Cranbury New Jersey 08512
United States
Employees -
Website http://www.amicusrx.com
Updated 07/08/2019
Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Financials

View All

John Francis Crowley
Chairman & Chief Executive Officer
Bradley L. Campbell
President, Chief Operating Officer & Director